Reactive oxygen species induce virus-independent MAVS-oligomerization in systemic lupus erythematosus

Buskiewicz, I. A. et al. (2016) Reactive oxygen species induce virus-independent MAVS-oligomerization in systemic lupus erythematosus. Science Signaling, 9(456), ra115. (doi: 10.1126/scisignal.aaf1933) (PMID:27899525)

122385.pdf - Accepted Version



The increased expression of genes induced by type I interferon (IFN) is characteristic of viral infections and systemic lupus erythematosus (SLE). We showed that mitochondrial antiviral signaling (MAVS) protein, which normally forms a complex with retinoic acid gene I (RIG-I)–like helicases during viral infection, was activated by oxidative stress independently of RIG-I helicases. We found that chemically generated oxidative stress stimulated the formation of MAVS oligomers, which led to mitochondrial hyperpolarization and decreased adenosine triphosphate production and spare respiratory capacity, responses that were not observed in similarly treated cells lacking MAVS. Peripheral blood lymphocytes of SLE patients also showed spontaneous MAVS oligomerization that correlated with the increased secretion of type I IFN and mitochondrial oxidative stress. Furthermore, inhibition of mitochondrial reactive oxygen species (ROS) by the mitochondria-targeted antioxidant MitoQ prevented MAVS oligomerization and type I IFN production. ROS-dependent MAVS oligomerization and type I IFN production were reduced in cells expressing the MAVS-C79F variant, which occurs in 30% of sub-Saharan Africans and is linked with reduced type I IFN secretion and milder disease in SLE patients. Patients expressing the MAVS-C79F variant also had reduced amounts of oligomerized MAVS in their plasma compared to healthy controls. Together, our findings suggest that oxidative stress–induced MAVS oligomerization in SLE patients may contribute to the type I IFN signature that is characteristic of this syndrome.

Item Type:Articles
Additional Information:This work was supported in part by research grants from the NIH (5P20 GM103496 to R.C.B., I.A.B., and A.K.; 5R01 HL086549 to S.A.H. and I.A.B.), Vermont Immunobiology and Infectious Diseases Center Pilot Project Grant (to A.K.), and the Lupus Research Institute (to R.C.B., I.A.B., and A.K.).
Glasgow Author(s) Enlighten ID:Hartley, Professor Richard
Authors: Buskiewicz, I. A., Montgomery, T., Yasewicz, E. C., Huber, S. A., Murphy, M. P., Hartley, R. C., Kelly, R., Crow, M. K., Perl, A., Budd, R. C., and Koenig, A.
College/School:College of Science and Engineering > School of Chemistry
Journal Name:Science Signaling
Publisher:American Association for the Advancement of Science
ISSN (Online):1937-9145
Copyright Holders:Copyright © 2016 The Authors
First Published:First published in Science Signaling 9(456): ra115
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record